InspireMD, Inc. (NYSE:NSPR) Short Interest Update

Key Points

• InspireMD, Inc. experienced a significant decrease in short interest, with a drop of 58.1% to 127,300 shares as of August 31, indicating a lower bearish sentiment among investors.
• Insider trading activity included Director Gary S. Roubin purchasing 41,322 shares and Director Paul Stuka acquiring 20,661 shares, reflecting confidence in the company's future.
• Currently, 44.78% of InspireMD's stock is held by institutional investors, indicating notable interest from larger market players.

InspireMD, Inc. (NYSE:NSPR - ) saw a large drop in short interest in the month of August. As of August 31st, there was short interest totaling 127,300 shares, a drop of 58.1% from the August 15th total of 304,000 shares. Currently, 0.7% of the shares of the stock are sold short. Based on an average trading volume of 180,500 shares, the short-interest ratio is presently 0.7 days. Based on an average trading volume of 180,500 shares, the short-interest ratio is presently 0.7 days. Currently, 0.7% of the shares of the stock are sold short.

Insider Transactions at InspireMD

In other news, Director Gary S. Roubin purchased 41,322 shares of the business's stock in a transaction that occurred on Wednesday, July 30th. The stock was purchased at an average cost of $2.42 per share, with a total value of $99,999.24. Following the acquisition, the director directly owned 608,425 shares of the company's stock, valued at approximately $1,472,388.50. This trade represents a 7.29% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Paul Stuka purchased 20,661 shares of the business's stock in a transaction that occurred on Wednesday, July 30th. The shares were purchased at an average cost of $2.42 per share, with a total value of $49,999.62. Following the completion of the acquisition, the director directly owned 444,195 shares in the company, valued at $1,074,951.90. The trade was a 4.88% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders acquired 103,304 shares of company stock valued at $249,996. Company insiders own 34.06% of the company's stock.

Hedge Funds Weigh In On InspireMD

Several institutional investors have recently added to or reduced their stakes in NSPR. Huntleigh Advisors Inc. raised its stake in shares of InspireMD by 5.8% in the second quarter. Huntleigh Advisors Inc. now owns 124,228 shares of the company's stock worth $282,000 after acquiring an additional 6,821 shares during the last quarter. Brown Advisory Inc. bought a new position in shares of InspireMD in the first quarter worth about $27,000. Uniting Wealth Partners LLC bought a new position in shares of InspireMD in the first quarter worth about $27,000. Raymond James Financial Inc. raised its stake in shares of InspireMD by 28.9% in the second quarter. Raymond James Financial Inc. now owns 44,604 shares of the company's stock worth $101,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Rosalind Advisors Inc. raised its stake in shares of InspireMD by 0.6% in the second quarter. Rosalind Advisors Inc. now owns 2,289,099 shares of the company's stock worth $5,196,000 after acquiring an additional 14,109 shares during the last quarter. 44.78% of the stock is owned by institutional investors.

InspireMD Trading Down 1.7%

NSPR stock traded down $0.04 during trading on Friday, hitting $2.38. 46,340 shares of the stock traded hands, compared to its average volume of 99,962. InspireMD has a one year low of $1.99 and a one year high of $3.80. The stock has a market cap of $99.30 million, a price-to-earnings ratio of -3.17 and a beta of 0.68. The company has a 50 day simple moving average of $2.44 and a 200 day simple moving average of $2.53.

About InspireMD

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.